New drugs in recurrent high grade gliomas

Background: The incidence of Central Nervous System (CNS) neoplasias ranges from 3.8 to 5.1 cases per 100,000 inhabitants. In the presence of recurren ce, the treatment is problematic; chemotherapy is experimental primarily be cause the response is palliative and of limited duration. Materials and Met hods: This article analytes the new drugs that have been introduced for the treatment of these patients in recent years, the objective response the TT P and the MST. Results: The most encouraging results to date come from stud ies of temozolomide, which is one of the most active and best tolerated dru gs in recent years. Conclusion: New approaches to chemotherapy treatment ar e necessary. Enrollment of patients into rigorous, well-conducted, clinical trials, both at tumor diagnosis and after armor recurrence will generate n ew information regarding investigational therapies and may offer improved t herapies for patients with malignant gliomas.